Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
depression
Biotech
Seaport, Hemab prepare IPOs to fund depression, clotting drugs
Seaport Therapeutics and Hemab Therapeutics are both charting a course for the public markets.
James Waldron
Apr 13, 2026 7:12am
FDA approves 1st nondrug, at-home treatment for depression
Dec 11, 2025 6:00am
Reunion's psychedelic reduces postpartum depression in ph. 2
Aug 18, 2025 7:52am
Beckley Psytech psychedelic reduces depression symptoms in ph. 2
Jul 1, 2025 8:30am
Gilgamesh links psychedelic to 94% remission rate in depression
May 27, 2025 11:00am
Neumora rethinks depression drug strategy after ph. 3 failure
Mar 3, 2025 11:00am
